This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zimmer Biomet Set to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
ZBH's Hips business is expected to have witnessed growth banking on its suite of navigation solutions in direct anterior stems and surgical impactors.
Labcorp Set to Report Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
In the fourth quarter of 2024, LH is likely to have witnessed strong growth in both diagnostics and biopharma laboratory services.
Edwards Lifesciences Q4 Earnings Set to Benefit From TAVR Growth
by Zacks Equity Research
Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter.
TECH Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
In the second quarter, Bio-Techne is expected to have witnessed the stabilization of large-pharma customers and an increase in biotech customers' ordering trends.
Will Merit Medical (MMSI) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Merit Medical (MMSI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Merit Medical Systems, Inc. (MMSI) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Breast Health Performance Likely to Aid Hologic's Q1 Earnings
by Zacks Equity Research
In the first quarter of fiscal 2025, HOLX is expected to have benefited from expanding breast health offerings.
Cardinal Health to Report Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Despite recent supply-chain challenges, new facilities and growth in branded and specialty pharmaceutical sales are likely to have driven CAH's performance in the fiscal second quarter.
Premier Protein Momentum Likely to Fuel BellRing Brands' Q1 Earnings
by Zacks Equity Research
BRBR is expected to have gained from strong volume growth for Premier Protein in the first quarter of fiscal 2025.
HCA Healthcare's Q4 Earnings Beat Estimates on Strong Admissions
by Zacks Equity Research
HCA's Q4 results benefit from improved equivalent admissions and inpatient surgeries, partly offset by the impact of hurricanes and higher salaries and benefits expenses.
Quest Diagnostics Q4 Earnings Preview: What's in Store for the Stock?
by Zacks Equity Research
Quest Diagnostics is likely to have driven strong performances in the key physician and hospital channels in the fourth quarter of 2024.
Here's Why Merit Medical (MMSI) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Reasons Why Growth Investors Shouldn't Overlook Merit Medical (MMSI)
by Zacks Equity Research
Merit Medical (MMSI) could produce exceptional returns because of its solid growth attributes.
BDX or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BDX vs. MMSI: Which Stock Is the Better Value Option?
Here's Why Merit Medical (MMSI) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cardinal Health, Inc. (CAH) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why it is Prudent for Investors to Hold Humana Stock for Now
by Zacks Equity Research
HUM remains well-poised for growth, attributable to improved premiums, contract wins, acquisitions, collaborations and growing cash reserves.
Merit Medical Stock Gains Following Solid Preliminary Q4 Revenues
by Zacks Equity Research
MMSI's revenue growth in the fourth quarter is likely to have been boosted by continued robust adoption of its products.
Compelling Reasons to Retain Acadia Healthcare Stock Now
by Zacks Equity Research
ACHC remains well-poised for growth, attributable to sustained demand for behavioral healthcare services, as well as growth initiatives such as acquisitions, bed additions and joint ventures.
Is Merit Medical (MMSI) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Merit Medical (MMSI) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why You Should Add MMSI Stock to Your Portfolio Now
by Zacks Equity Research
Merit Medical's strong product portfolio raises optimism about the stock.
BDX vs. MMSI: Which Stock Is the Better Value Option?
by Zacks Equity Research
BDX vs. MMSI: Which Stock Is the Better Value Option?
Here's Why Merit Medical (MMSI) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Merit Medical Stock Rises Following FDA Nod for WRAPSODY Device
by Zacks Equity Research
MMSI announces FDA approval for the WRAPSODY Cell-Impermeable Endoprosthesis.
STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot
by Zacks Equity Research
Stereotaxis' latest regulatory approval in China is likely to offer a minimally-invasive treatment solution for complex arrhythmia patients and improve global cardiovascular care.